Botswana-Harvard T.H. Chan School of Public Health AIDS Initiative Partnership CTU
Project Number5UM1AI069456-19
Contact PI/Project LeaderLOCKMAN, SHAHIN Other PIs
Awardee OrganizationHARVARD SCHOOL OF PUBLIC HEALTH
Description
Abstract Text
Summary/Abstract
This is an application to renew a Clinical Trials Unit (CTU) in Botswana that will conduct research related
to adult and pediatric HIV therapeutic strategies; interventions to address HIV-associated
infections/conditions in pediatric and maternal populations; treatment and prevention of tuberculosis in
adults (including pregnant women) and children with and without HIV; and integrated HIV prevention
strategies in pediatric and adult populations.
These activities will occur through participation in three research networks: 1) the HIV/AIDS Adult
Therapeutics Clinical TrialsNetwork; 2) HIV/AIDS Maternal, Adolescent and Pediatric Therapeutics
Clinical TrialsNetwork, and 3) the HIV Prevention Clinical TrialsNetwork. We will perform multi-center
studies at our two established CRSs: one in Gaborone (all 3 networks), the capital city of Botswana, and
the other in Molepolole (Maternal, Adolescent and Pediatric Therapeutics network only), the largest
village in Botswana. We will thus work with both urban and village populations of all ages and of both
sexes.
The primary objective of this proposal is therefore to renew a CTU in Botswana that will participate in and
contribute to the following high-impact areas of research:
Novel and durable treatments for HIV in adults (including pregnant women) and children
Strategies to induce ART-free HIV remission (or eradication) in adults and children
Treatment and prevention of HIV-related complications and co-infections in adults and children
New treatments / modalities and prevention approaches for tuberculosis in adults and children
HIV prevention strategies, including pre-exposure prophylaxis and integrated prevention approaches
Within each of these research areas, this CTU will contribute significantly to:
Enrolling participants into and conducting high-quality clinical research studies,
Participating in network activities, including protocol teams and scientific / resource committees, and
Conceiving and proposing new, relevant, high-impact studies in priority areas
Public Health Relevance Statement
Project Narrative
The Botswana Clinical Trials Unit will develop and study strategies for preventing and treating HIV infection
and HIV-related illnesses, including tuberculosis, that are relevant to the severe HIV epidemic in sub-Saharan
Africa and elsewhere. This will include studies of novel and durable HIV treatment in HIV-infected adults,
including pregnant women, and children; strategies to induce antiretroviral-free HIV remission (or eradication)
in adults and children; new treatments and prevention approaches for tuberculosis in adults, including pregnant
women, and children; and HIV prevention strategies, including pre-exposure prophylaxis and integrated
prevention approaches.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS clinical trial groupAIDS preventionAcquired Immunodeficiency SyndromeAddressAdolescentAdultAfrica South of the SaharaAfricanAgeAnti-Retroviral AgentsAreaBotswanaCapitalChildChildhoodCitiesClinical ResearchClinical TrialsNetworkClinical Trials UnitCollaborationsCommunitiesCommunity Health EducationDisease remissionEnrollmentEpidemicEthicsGrantHIVHIV InfectionsHIV Vaccine TrialsNetworkHIV/AIDSHuman ResourcesIndividualInfantInfectionInfusion proceduresInstitutionInternationalInternational AgenciesInternational Maternal Pediatric Adolescent AIDS Clinical TrialsInterventionLaboratoriesLeadLeadershipMentorsModalityMulticenter StudiesPatient RecruitmentsPopulationPregnant WomenPreventionPrevention approachPrevention strategyProtocols documentationPublic Health SchoolsQuality ControlResearchResearch PersonnelResourcesSiteTechniquesTherapeuticTherapeutic Clinical TrialTrainingTuberculosisWorkco-infectioncommunity engagementdata managementdata qualityexperiencenovelparticipant enrollmentpediatric human immunodeficiency virusplacebo controlled trialpre-exposure prophylaxispreventquality assurancerandomized trialresearch studysex
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
149617367
UEI
UNVDZNFA8R29
Project Start Date
01-February-2007
Project End Date
30-November-2027
Budget Start Date
01-December-2024
Budget End Date
30-November-2025
Project Funding Information for 2025
Total Funding
$1,055,576
Direct Costs
$979,393
Indirect Costs
$76,183
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Allergy and Infectious Diseases
$1,055,576
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5UM1AI069456-19
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5UM1AI069456-19
Patents
No Patents information available for 5UM1AI069456-19
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5UM1AI069456-19
Clinical Studies
No Clinical Studies information available for 5UM1AI069456-19
News and More
Related News Releases
No news release information available for 5UM1AI069456-19
History
No Historical information available for 5UM1AI069456-19
Similar Projects
No Similar Projects information available for 5UM1AI069456-19